Qantas Biopharma Private Limited

Medical product trading company established in 2020 with registered office in Hisar, Haryana.

2020 | Hisar, Haryana (India) | Active
Last Updated: December 20, 2024

Qantas Biopharma Profile

Key Indicators

  • Authorised Capital ₹ 1.50 M
  • Paid Up Capital ₹ 0.50 M
  • Company Age 4 Year, 4 Months
  • Last Filing with ROC 31 Mar 2024

About Qantas Biopharma

Qantas Biopharma Private Limited (QBPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 October 2020 (Four years and four months 9 days old ). Its registered office is in Hisar, Haryana, India.

The Company is engaged in the Healthcare Industry.

The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.

Ritu and Shakuntla serve as directors at the Company.

Company Details

  • Location

    Hisar, Haryana, India

  • Telephone

    +91-XXXXXXXXXX

  • Email Address

  • Website

    -

  • Social Media
    -

Corporate Identity Details

  • CIN/LLPIN

    U73100HR2020PTC090217

  • Company No.

    090217

  • Company Classification

    Private Limited Indian Non-Government Company

  • Incorporation Date

    17 Oct 2020

  • Date of AGM

    30 Sep 2024

  • Date of Balance Sheet

    31 Mar 2024

  • Listing Status

    Unlisted

  • ROC Code

    Roc Delhi

Industry

Healthcare

Who are the key members and board of directors at Qantas Biopharma?

Board Members (2)

NameDesignationAppointment DateStatus
Ritu Country flag representing In Director 17-Oct-2020Current
Shakuntla Country flag representing In Director 17-Oct-2020Current

Financial Performance of Qantas Biopharma.

Qantas Biopharma Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.

Graph illustrating revenue growth over time
Graph showing profit and loss trends over time
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023)YOY Growth
(FY 2022)(FY 2021)(FY 2020)(FY 2019)
Total Revenue
Revenue from Operations
Total Assets
Profit or Loss
Net Worth
EBITDA

What is the Ownership and Shareholding Structure of Qantas Biopharma?

In 2021, Qantas Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Indicator graph

Charges (Loans)

Placeholder for charges-related data

There are no open charges registered against the company as per our records.

How Many Employees Work at Qantas Biopharma?

Qantas Biopharma has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Graph showing employee growth trends

Deals i

Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Qantas Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Qantas Biopharma's trajectory.

Rating

Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Latest Updates, News, and FAQs on Qantas Biopharma

Recent activity within the organization

  • Annual General Meeting

    Qantas Biopharma Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.

    30 Sep 2024

  • Balance Sheet

    Qantas Biopharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi.

    31 Mar 2024

  • Director Appointment

    Ritu was appointed as a Director was appointed as a Director on 17 Oct 2020 & has been associated with this company since 4 years 4 months .

    17 Oct 2020

  • Director Appointment

    Shakuntla was appointed as a Director was appointed as a Director on 17 Oct 2020 & has been associated with this company since 4 years 4 months .

    17 Oct 2020

  • Company Incorporation

    Qantas Biopharma Private Limited was registered on 17 Oct 2020 with Roc Delhi & aged 4 years 4 months as per MCA records.

    17 Oct 2020

Frequently asked questions

  • Qantas Biopharma Private Limited was incorporated on 17 Oct 2020.

  • The authorized share capital of Qantas Biopharma Private Limited is ₹ 1.50 M and paid-up capital is ₹ 0.50 M.

  • Currently 2 directors are associated with Qantas Biopharma Private Limited.

    • Ritu
    • Shakuntla
  • As per Ministry of Corporate Affairs (Mca), the registered address of Qantas Biopharma Private Limited is Shop No.39 Surya Pharma Suraj Market, Katla India, Hisar, Haryana, 125001.

  • The corporate identification number (CIN) of Qantas Biopharma Private Limited is U73100HR2020PTC090217 and the company number is 090217 as per Ministry of Corporate Affairs (MCA).

  • The most recent Balance Sheet for Qantas Biopharma Private Limited was filed with the ROC on 31 Mar 2024.